NRNadia Rosencher

Nadia Rosencher

*This is an algorithmically generated author record based on publicly available information.

Nadia Rosencher has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery

    by Nadia Rosencher, Dominique Poisson, Aline Albi, Martine Aperce, Jeanne Barré, Charles Marc Samama

    The primary objective of this study was to assess the number of erythropoietin (EPO) injections required to reach a hematocrit (Ht) of 40% in moderately anemic patients. The secondary objective was to compare this strategy with autologous blood donation (ABD) in elective orthopedic surgery in terms of red blood cell (RBC) production. 93 patients with a baseline Ht between 30 and 39% were randomized into two groups the day of the preoperative assessment. In the EPO group, patients received 40,000 UI/week sc until they reached a maximal Ht of 40%. In the ABD group, a RBC pack was collected every week as long as the Ht was above 33%. Two EPO injections were necessary to reach a 40% Ht in 63% of the patients. It was possible to collect two RBC packs in 45% of the patients in the ABD group. Volume of RBC production was significantly higher in the EPO group: 268 ± 142 mL vs 141 ± 129 (P = 0.0001). In the EPO group, Ht was significantly higher on days one and three after surgery and at discharge. The energy score was better in the EPO group. In the ABD group, 12.6% patients vs 6.5% in the EPO group received allogeneic transfusion (ns). Only two EPO injections were sufficient to reach a Ht of 40% in the majority of patients. Therefore, to improve cost/effectiveness, the number of EPO injections should be related to baseline Ht instead of the four injections recommended in the product monograph. Évaluer le nombre d’injections d’érythropoïétine (EPO) nécessaires pour atteindre un hématocrite (Ht) de 40% chez des patients modérément anémiques. Aussi, comparer cette stratégie avec le don de sang autologue (DSA) en chirurgie orthopédique réglée en termes de production de globules rouges (GR). Des patients (n = 93) présentant un Ht de base de 30 à 39% ont été répartis en deux groupes le jour de l’évaluation préopératoire. Ceux du groupe EPO ont reçu 40,000 UI/semaine sc jusqu’à ce qu’ils présentent un Ht maximal de 40%. Dans le groupe DSA, un culot globulaire a été prélevé chaque semaine tant que l’Ht était au-dessus de 33%. Il a fallu deux injections d’EPO pour atteindre un Ht de 40% chez 63% des patients. Il a été possible de prélever deux culots chez 45% des patients du groupe DSA. Le volume de production de GR a été significativement plus élevé chez ceux du groupe EPO: 268 ± 142mL vs 141 ± 129 (P = 0,0001). Dans le groupe EPO, l’Ht a été significativement plus élevé aux jours un et trois après l’opération et au moment du congé. Le score d’asthénie était moins prononcé dans le groupe EPO. Une transfusion allogénique a été faite chez 12,6% des patients du groupe DSA vs 6,5% du groupe EPO (ns). Il a suffi de deux injections d’EPO seulement pour atteindre un Ht de 40% chez la majorité des patients. Donc, pour améliorer l’efficacité des coûts, il faudrait relier le nombre d’injection d’EPO à l’Ht de base plutôt que de faire les quatre injections recommandées dans la monographie du produit.


  • Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations

    by N. Rosencher

    Summary: The oral direct thrombin inhibitor ximelagatran shows great promise for prevention of venous thromboembolic events following major elective orthopaedic surgery. Its consistent and predictable pharmacokinetics and pharmacodynamics across a wide range of patient populations allow administration with fixed dosing and with no coagulation monitoring. In orthopaedic surgery clinical trials, ximelagatran was effective and well tolerated compared with standard therapy, with dose and timing relative to surgery important factors in determining its optimal profile. In European trials, an initial 3‐mg postoperative dose of subcutaneous melagatran, the active form of ximelagatran, followed by oral ximelagatran 24 mg twice daily achieved similar efficacy and safety to enoxaparin. Although the risk of spinal haematoma following neuraxial anaesthesia is rare, it is increased by the concomitant use of anticoagulants. In orthopaedic surgery trials with ximelagatran to date, complications such as spinal haematoma have not been reported. The pharmacokinetic profile of ximelagatran suggests that concurrent use with neuraxial anaesthesia should require no further precautions than those currently necessary with low‐molecular‐weight heparin.


  • Top Cited Papers

    Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe*

    by Nadia Rosencher, Hans E.M. Kerkkamp, G. Macheras, L.M. Munuera, G. Menichella, David M. Barton, Saskia Cremers, Ivo L. Abraham, For The Ostheo Investigation

    BACKGROUND: The purpose of this study was to assess current practices in blood management in elective orthopedic surgery in Europe. STUDY DESIGN AND METHODS: For this 225‐center prospective survey, data were collected on 3996 patients. Actual perioperative blood loss was compared to preoperative estimates. Differences in Hb levels and other outcome variables for patients receiving allogeneic versus autologous transfusions were evaluated. The probability of allogeneic transfusion based on selected predictor variables was estimated. RESULTS: A total of 2640 (67%) hip and 1305 (33%) knee arthroplasty patients were evaluated. Estimated blood loss (median, 750 mL) was significantly lower than computed blood loss (median, 1944 mL). A total of 2762 (69%) patients received transfusions, including 1393 (35%) autologous‐only and 1024 (25%) allogeneic‐only. The probability of allogeneic transfusion decreased with increasing baseline Hb, but differentially so for men and women. Transfusion triggers were Hb levels of 8.93 ± 1.83 g per dL for allogeneic transfusions, and 21 percent of these occurred when the Hb level was greater than 10 g per dL. Autologous blood transfusion was associated with a significantly lower rate (1%) of wound infections than allogeneic blood transfusion (4.2%). CONCLUSION: Accurate assessment of preoperative Hb levels, better estimation of perioperative blood loss, efficient use of autologous blood, adherence to transfusion guidelines, and pharmacologic alternatives contribute to effective and comprehensive blood and anemia management.


  • Orthopaedic Surgery Transfusion Haemoglobin European Overview: the OSTEO study (extended abstract)

    by N Rosencher, K.J Boucebci, G Menichella, H Kerkkamp, G Macheras, L Munuera, D Barton, S Cremers, I Abraham